Six patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2039. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2039
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2022 to 2043.202620302034203820422043
9 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2041 · High confidence
Also notable
Ends Aug 2039 · High confidence
Also notable
Ends Jan 2043 · High confidence
Engineered ANTI-IL-2 Antibodies
US 11,851,485
A family of 5 related applications built on the 2023 grant. Protection runs to 2041.
Computer Assisted Antibody Re-Epitoping
US 11,468,969
The earliest of the three still in force, granted 2022 and renewed since. Its term ends first, in 2039.
Engineered Dual Binding Antibodies and Uses Thereof
US 12,686,714
A family of 5 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 26, 2027The maintenance fee for Engineered ANTI-IL-2 Antibodies (US 11,851,485) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Engineered ANTI-IL-2 Antibodies | 3 in force | to Jun 2041 |
| Anti-Tumor Necrosis Factor Receptor (TNFR2) Antibodies and Uses Thereof | 1 in force | to Aug 2043 |
| Engineered Dual Binding Antibodies and Uses Thereof | 1 in force | to Jan 2043 |
| Computer Assisted Antibody Re-Epitoping | 1 in force | to Aug 2039 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,468,969 | Computer Assisted Antibody Re-Epitoping In force · High confidence | In force | High confidence | |
| US 11,851,485 | Engineered ANTI-IL-2 Antibodies In force · High confidence | In force | High confidence | |
| US 12,275,784 | Engineered ANTI-IL-2 Antibodies In force · High confidence | In force | High confidence | |
| US 12,312,400 | Engineered ANTI-IL-2 Antibodies In force · High confidence | In force | High confidence | |
| US 12,686,714 | Engineered Dual Binding Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,753,240 | Anti-Tumor Necrosis Factor Receptor (TNFR2) Antibodies and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 9 applications pending. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.